

No	Research Ethics Committee Reference Number	IRAS Number	Name of Trial	Target Number of Patients Agreed?	Minimum Patients	Maximum Patients	Date Agreed to recruit target number of patients available	Date agreed to recruit target number of patients	Total number patients recruited at target date	Date Trial closed to recruitment	Total number of study participants recruited	Reason for closure
1	15/WA/0465	189501	Expanding MRI Access for Patients with New and Existing ICDs and CRT-Ds (ENABLE MRI, C17241)	Number Agreed	5	5	Date Agreed	30/09/2016	3	10/08/2017	3	Recruitment Finished
2	16/YH/0074	199143	Evaluation of a Multi-Electrode Linear Type Catheter (D-1368-01-SI) for Endocardial Ablation of Patients with Persistent Atrial Fibrillation (LMF-167)	Range Agreed	10	16	Date Agreed	31/01/2017	4	13/06/2017	4	Withdrawn by Host
3	16/LO/0871	195195	Assessing clinical outcomes using the EDWARDS INTUITY Elite Valve System in isolated AVR using minimally invasive surgery in a European multi-center, active, post-market registry.	Range Agreed	10	30	Date Agreed	31/12/2017	8	13/06/2017	8	Recruitment Finished
4	16/LO/1112	204396	A Phase III, randomised, double-blind, multicentre, parallel group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus enofovir/emtricitabine in HIV-1-infected treatment-naïve adults	Range Agreed	1	5	Date Agreed	31/12/2016	3	28/03/2017	4	Recruitment Finished
5	14/WM/1029	157257	A Prospective, Observational Drug Utilization Study of Stribild in Adults with HIV-1 Infection	Number Agreed	20	20	Date Agreed	30/11/2015	18	28/06/2017	21	Recruitment Finished
6	14/SW/0115	147449	VIRTUS – OUS-Safety and Efficacy of the Veniti Vici™ Venous Stent System (Veniti Inc.) when Used to Treat Clinically Significant Chronic Non-malignant Obstruction of the Iliofemoral Venous Segment	Range Agreed	1	15	Date Agreed	03/09/2018	18	17/11/2016	18	Withdrawn by sponsor
7	16/LO/1045	201246	The BARD® VENOVO™ Venous Stent Study – A Prospective, Non-Randomized, Multi-Center, Single-Arm Study of the Treatment of Iliofemoral Occlusive Disease – an Assessment for Effectiveness and Safety (VERNAQUARI)	Number Agreed	5	5	Date Agreed	30/06/2017	9	01/05/2017	9	Recruitment Finished
8	09/H0402/101	22522	A Randomized, Multicenter, Double-Blind, Parallel, Placebo-controlled Study of the Effects of JNJ 28431754 on Cardiovascular Outcomes in Adult Subjects with Type 2 Diabetes Mellitus (The CANVAS Trial: CANagliflozin CardioVascular Assessment Study)	Range Agreed	1	12	Not Available/Not Agreed	Not Available/Not Agreed	n/a	22/02/2017	4	Recruitment Finished
9	16/EE/0130	200989	Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid® in Adults with Type 1 Diabetes	Range Agreed	1	3	Date Agreed	04/01/2017	7	13/01/2017	7	Recruitment Finished
10	16/EE/0011	194393	A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 EFFICACY AND SAFETY STUDY OF OTO-104 GIVEN AS A SINGLE INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE	Range Agreed	1	5	Date Agreed	28/02/2017	3	06/09/2017	3	Withdrawn by sponsor
11	16/EE/0243	207331	A 6-MONTH, MULTICENTER, PHASE 3, OPEN-LABEL EXTENSION SAFETY STUDY OF OTO-104 GIVEN AT 3-MONTH INTERVALS BY INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE	Range Agreed	1	5	Date Agreed	31/07/2017	2	06/02/2017	2	Withdrawn by sponsor
12	16/ES/0130	211515	A randomized, 24-week treatment, double-blind, placebo-controlled efficacy and safety study of dupilumab 300 mg every other week, in patients with bilateral nasal polyposis on a background therapy with intranasal corticosteroids	Number Agreed	2	2	Date Agreed	31/08/2017	6	05/07/2017	6	Recruitment Finished
13	15/YH/0287	174975	AN OPEN-LABEL STUDY OF DUPIXUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPIXUMAB CLINICAL TRIALS	Number Agreed	1	1	Date Agreed	31/07/2016	4	02/11/2016	4	Withdrawn by Sponsor
14	16/WM/0247	202461	APPRECIATE (APREmilast Clinical Treatment Experience in psoriasis): A Multi-centre, Retrospective Observational Study of Real-World Experience of Psoriasis Patients Treated with Apremilast in Clinical Dermatology Practice	Range Agreed	7	10	Date Agreed	31/12/2016	6	30/06/2017	8	Recruitment Finished
15	16/LO/0779	203698	An open label, multicenter, extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria patients who completed study CGE031C2201	Number Agreed	1	1	Date Agreed	20/03/2017	0	13/06/2017	0	Recruitment Finished
16	16/LO/0129	192559	Multicentre, non-controlled, prospective, post-marketing safety study following long-term prophylactic Optivate® treatment in subjects with severe haemophilia A	Range Agreed	2	5	Date Agreed	30/06/2016	0	26/06/2017	0	Recruitment Finished
17	15/LO/1441	186018	A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura	Number Agreed	1	1	Date Agreed	30/04/2017	0	29/04/2017	0	Recruitment Finished
18	11/SC/0059		A Phase Ib, open-label, dose-finding study of the JAK inhibitor INC424 tablets administered orally to patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) and baselineplatelet counts = 50 x109/l and	Number Agreed	3	3	Date Agreed	01/05/2014	0	13/02/2017	6	Recruitment Finished
19	13/YH/0201	129722	The efficacy, safety and tolerability of Sativex as an adjunctive treatment to existing anti-spasticity medications in children aged 8 to 18 years with spasticity due to cerebral palsy or traumatic brain injury who have not responded adequately to their existing anti-spasticity medications: a parallel group randomised, double-blind, placebo-controlled study followed by a 6-month open label extension phase.	Number Agreed	16	16	Date Agreed	01/03/2013	5	07/03/2017	20	Recruitment Finished
20	14/EM/1071	159417	Multicenter, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled 4 weeks extension phase in paediatric patients with sickle cell disease	Number Agreed	3	3	Date Agreed	30/06/2015	2	14/10/2016	4	Recruitment Finished
21	16/LO/0361	193839	Characterised oral desensitisation immunotherapy (CODIT) for peanut-allergic children and adults using AR101, a pharmaceutical-grade peanut allergen formulation.	Range Agreed	5	12	Date Agreed	30/11/2017	11	08/12/2016	11	Withdrawn By Sponsor
22	16/EM/0241	199226	A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia	Range Agreed	2	3	Date Agreed	30/09/2017	3	29/09/2017	3	Recruitment Finished
23	16/LO/0537	191351	A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults with Dravet Syndrome	Number Agreed	1	1	Date Agreed	30/11/2016	0	12/06/2017	0	Withdrawn by sponsor
24	15/LO/1500	187068	Investigation of drug-drug interaction between nintedanib and pifredone in patients with IPF (an open label, multiple-dose, two group study followed by nintedanib open label treatment)	Number Agreed	5	5	Date Agreed	31/07/2016	5	14/04/2017	5	Recruitment Finished
25	17/EM/0014	219556	Prospective Clinical Investigation for a Randomized, Controlled, Multicenter Non-inferiority study comparing standard wound closure technique with drains (control) to standard wound closure techniques with TissuGlu and no drains (test) in Mastectomy.	Range Agreed	5	10	Date Agreed	31/07/2017	1	29/09/2017	1	Recruitment Finished

No	Research Ethics Committee Reference Number	IRAS Number	Name of Trial	Target Number of Patients Agreed?	Minimum Patients	Maximum Patients	Date Agreed to recruit target number of patients available	Date agreed to recruit target number of patients	Total number patients recruited at target date	Date Trial closed to recruitment	Total number of study participants recruited	Reason for closure
26	13/NW/0003	117310	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF ART123 IN SUBJECTS WITH SEVERE SEPSIS AND COAGULOPATHY	Range Agreed	1	2	Date Agreed	30/04/2015	0	08/03/2017	0	Recruitment Finished
27	15/LO/0099	164654	A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin in Mechanically Ventilated Adult Subjects	Range Agreed	1	3	Date Agreed	01/09/2018	0	31/01/2017	0	Withdrawn by Host
28	15/EE/0464	183877	A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LIPC-501 in Patients with Catecholamine-Resistant Hypotension (CRH)	Range Agreed	1	3	Date Agreed	30/09/2016	8	30/11/2016	8	Recruitment Finished
29	13/WM/0451	136690	A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety and Pharmacokinetics of AMG337 in Subjects with MET Amplified Gastric/Gastroesophageal junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumours	Range Agreed	1	3	Date Agreed	31/05/2015	0	30/10/2016	0	Recruitment Finished
30	15/NW/0152	169540	A multicentre, open-label, single-arm safety study of Herceptin® SC in combination with Perjeta® and Docetaxel in treatment of patients with HER2-positive advanced breast cancer (metastatic or locally recurrent)	Range Agreed	1	5	Date Agreed	31/10/2016	3	27/01/2017	3	Recruitment Finished
31	15/LO/1787	188394	A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)	Range Agreed	1	4	Date Agreed	01/06/2017	8	30/11/2016	8	Recruitment Finished
32	16/NE/0027	187317	A phase 3, multicenter, randomized, open-label study of avelumab (MSB0010718C) alone or in combination with Pegylated Liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin alone in patients with platinum resistant/refractory ovarian cancer	Range Agreed	1	6	Date Agreed	30/11/2016	6	19/04/2017	10	Recruitment Finished
33	15/EM/0344	183906	A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatumimab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma	Range Agreed	1	3	Date Agreed	31/03/2017	0	11/01/2017	0	Withdrawn By Sponsor
34	16/EM/0198	199630	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER	Range Agreed	1	4	Date Agreed	31/10/2017	3	31/05/2017	3	Recruitment Finished
35	15/EE/0448	189797	Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma	Number Agreed	5	5	Date Agreed	07/06/2017	6	30/06/2017	6	Recruitment Finished
36	14/EM/0081	143454	A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men who are at High Risk for Poor Clinical Outcomes after Experiencing Biochemical Failure Following Definitive Prostate Outcomes Following Definitive Prostate Cancer Therapy, Men with Castration-Resistant Prostate Cancer and Men with Metastatic Prostate Cancer at Initial Diagnosis	Range Agreed	25	25	Date Agreed	30/12/2015	2	30/11/2016	2	Recruitment Finished
37	16/YH/0313	211601	Clinical Research Study to Determine Effect of Arginine on Plaque Adhesive Properties	Range Agreed	34	45	Date Agreed	31/03/2017	48	02/06/2017	53	Recruitment Finished
38	16/EE/0152	197981	A pilot study to evaluate a soft tissue-healing model.	Number Agreed	10	10	Date Agreed	31/07/2016	13	08/02/2017	13	Withdrawn by sponsor
39	16/LO/1259	199166	Clinical evaluation of a commercially-available professional gel for treatment of periodontal patients	Range Agreed	10	20	Date Agreed	31/09/2016	32	12/04/2017	32	Recruitment Finished
40	12/NE/0412	118819	A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN305, a Humanised Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function	Range Agreed	35	35	Date Agreed	30/09/2015	24	21/02/2017	24	Recruitment Finished
41	15/LO/0189	160291	European Multicentre Kidney Transplant Advagraf Conversion Registry. A non-interventional post-authorisation study (PAS)	Number Agreed	10	10	Date Agreed	31/12/2017	0	20/04/2017	0	Withdrawn by Sponsor
42	16/WM/0215	203334	An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison with PTFE Grafts as Conduits for Hemodialysis (HUMANITY)	Range Agreed	10	15	Date Agreed	31/07/2017	7	31/08/2017	9	Recruitment Finished